Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …

Cancers develop within complex tissue environments consisting of diverse innate and
adaptive immune cells, along with stromal cells, vascular networks, and many other cellular …

Immunotherapy has become a key therapeutic strategy in the treatment of many cancers. As
a result, research efforts have been aimed at understanding mechanisms of resistance to …

In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …

Epigenetics is dynamic and heritable modifications to the genome that occur independently
of DNA sequence. It requires interactions cohesively with various enzymes and other …

The past decade has seen the emergence of immunotherapy as a prime approach to cancer
treatment, revolutionizing the management of many types of cancer. Despite the promise of …